Venture
Lyndra Therapeutics, Inc.
Latest Form D 2023-12-29- CIK 1679037
- State MA
- Biotechnology
- 5 Form D offerings since 2016-07-13
- Total sold
- $282M
- across 5 offerings
- Rounds
- 5
- Form D offerings since 2016-07-13
- Latest round
- $123M
- 2023-12-29 · 021-501189
- Investors
- 16
- on the latest round
Connected
named in its Form D filingsOfferings · since 2016-07-135 Form D offeringsExemptions506(b)People · Item 3Jessica Ballinger + 9 moreInvestors · dashboardInferred investors
Lyndra Therapeutics, Inc.CIK 1679037
Round timeline
amount sold · by first filed2023-12-29 · $123M
- 2016-07-13$23.1M021-266863
- 2019-01-28$55.2M021-331551
- 2021-06-23$60.5M021-403985
- 2023-06-07$20.4M021-483559
- 2023-12-29$123M021-501189
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($123M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-501189 | First filed2023-12-29 | Latest2023-12-29 | Sought$206M | Sold$123M | Investors16 | Exemptions506(b) |
| 021-483559 | First filed2023-06-07 | Latest2023-06-07 | Sought$179M | Sold$20.4M | Investors7 | Exemptions506(b) |
| 021-403985 | First filed2021-06-23 | Latest2021-06-23 | Sought$65M | Sold$60.5M | Investors22 | Exemptions506(b) |
| 021-331551 | First filed2019-01-28 | Latest2019-01-28 | Sought$60.9M | Sold$55.2M | Investors23 | Exemptions506(b) |
| 021-266863 | First filed2016-07-13 | Latest2017-04-19 | Sought$23.1M | Sold$23.1M | Investors15 | Exemptions506(b) |
Who backs Lyndra Therapeutics, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2023-12-29
| Name | Relationship |
|---|---|
| Jessica Ballinger | RelationshipExecutive Officer, Director |
| Amy Schulman | RelationshipDirector |
| Robert S. Langer | RelationshipDirector |
| Carlo Giovanni Traverso | RelationshipDirector |
| Zafi S. Avnur | RelationshipDirector |
| Doug Dachille | RelationshipDirector |
| Catherine Reynolds | RelationshipDirector |
| Helene Madonick | RelationshipDirector |
| Ashish Singh | RelationshipDirector |
| Patricia Hurter | RelationshipDirector |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- Massachusetts (MA)
- Exemptions
- Rule 506(b)
- First filed
- 2016-07-13
- Latest filing
- 2023-12-29
Who backs Lyndra Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗